2001
DOI: 10.1212/wnl.56.2.172
|View full text |Cite
|
Sign up to set email alerts
|

Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy

Abstract: Valproate monotherapy was associated with significantly greater weight gain than lamotrigine monotherapy. Weight gain associated with valproate was significant within 10 weeks after initiating therapy and continued throughout the study. Efficacy of lamotrigine was comparable with that of valproate; lamotrigine tended to be better tolerated.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
135
0
9

Year Published

2003
2003
2022
2022

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 217 publications
(153 citation statements)
references
References 34 publications
9
135
0
9
Order By: Relevance
“…Alterations in energy intake or expenditure can result from, or be associated with, changes in biological mechanisms, including hormone levels (Martin et al, 2009). Similar findings were observed in other studies also (Biton, et al, 2001;El-Khatib, et al, 2007;Kanemura et al, 2012). Monotherapy with Phenytoin caused hypocalcaemia in 4 and anemia in 3 patients respectively.…”
Section: Resultssupporting
confidence: 90%
“…Alterations in energy intake or expenditure can result from, or be associated with, changes in biological mechanisms, including hormone levels (Martin et al, 2009). Similar findings were observed in other studies also (Biton, et al, 2001;El-Khatib, et al, 2007;Kanemura et al, 2012). Monotherapy with Phenytoin caused hypocalcaemia in 4 and anemia in 3 patients respectively.…”
Section: Resultssupporting
confidence: 90%
“…Weight gain is a frequent problem, and increase in body weight and body mass index following VPA treatment have recently been studied (10,23). These studies show that weight gain occurs within the first ten weeks of treatment and is in the order of six kilograms (10,23).…”
Section: Dose-related Side Effectsmentioning
confidence: 99%
“…Weight gain is a frequent problem, and increase in body weight and body mass index following VPA treatment have recently been studied (10,23). These studies show that weight gain occurs within the first ten weeks of treatment and is in the order of six kilograms (10,23). Weight gain during VPA therapy is associated with metabolic changes like a decrease in â-oxidation of fatty acids (18), increased insulin and insulin/glucose ratios (31), and increased leptin and insulin levels (120).…”
Section: Dose-related Side Effectsmentioning
confidence: 99%
“…Of these, the clinically most important is the valproate-associated increase in body weight. This appears to be cumulative over the course of many years of treatment (Biton et al, 2001), and seems to be an important risk factor for the development of non-alcoholic fatty liver disease, which occurs in 61 % of patients (Luef et al, 2004). Valproate is a fatty acid derivative and competes with free fatty acids for albumin binding, and, as a GABAergic agonist, is known to be involved in insulin secretion from pancreatic beta-cells.…”
Section: Effects On Body Weightmentioning
confidence: 99%